Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10239918

    Cahuitamycins and methods of making and using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10238770

    Reparative cell isolation and delivery

    The Board of Regents of the University of Texas System · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10239837

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10239870

    Dopamine D3 receptor antagonists

    Indivior UK Limited · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10238750

    Porphyrin modified telodendrimers

    The Regents of the University of California · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10238749

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10238735

    Controlled activation of complement components for use as endogenous adjuvant

    PLS-Design GmbH · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10238734

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    The Regents of the University of California · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10238710

    Peptide having anti-inflammatory, osteogenic and hair growth promoting activities, and use of same

    CAREGEN CO., LTD. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10238674

    Bovine milk oligosaccharides

    The Regents of the University of California · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10238659

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10238655

    Dihydroindene and tetrahydronaphthalene compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10238626

    Therapeutic compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10238642

    Methods for treating neurogenic orthostatic hypotension

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10238646

    Methods for treating pruritus

    Trevi Therapeutics, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10238605

    Dry coated tablet

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10238599

    Composition and method for treating congenital cytomegalovirus induced hearing loss

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10238606

    Pharmaceutical compositions for the treatment of Helicobacter pylori

    RedHill Biopharma Ltd. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. IT 201700108526

    COMPOSIZIONI ORALI PER IL TRATTAMENTO DEL REFLUSO GASTROESOFAGEO.

    ALFASIGMA SPA [IT] · Granted Thu Mar 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10246463

    Hypoxia-inducible factor 1 (HIF-1) inhibitors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10246508

    Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

    CHEMOMAB LTD. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10249389

    Individual and cohort pharmacological phenotype prediction platform

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10245322

    Nanostructured carriers for guided and targeted on-demand substance delivery

    The Regents of the University of California · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10246483

    Bile acid analogs as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10245259

    Methods of treating RBP4 related diseases with triazolopyridines

    Belite Bio, Inc · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10246709

    Targeting ligands for therapeutic compounds

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10245255

    Compositions and methods for the treatment of obesity and related disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10246713

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10246707

    Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means

    BIOMARIN TECHNOLOGIES B.V. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10246514

    Single domain antibodies that bind to human CD20

    United States of America as represented by the Secretary of the Air Force · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10246708

    Dosages and methods for delivering lipid formulated nucleic acid molecules

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10246509

    Restricted immunoglobulin heavy chain mice

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10246505

    Chimeric antigen receptors to control HIV infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10246471

    ETP derivatives

    The Regents of the University of California · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10246464

    Thienopyrimidine and thienopyridine compounds and methods of use thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10246416

    Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides

    Akebia Therapeutics, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10246453

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10245330

    Compositions and methods for imaging

    The Regents of the University of California · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. DE 102017122807

    Orales Schilddrüsentherapeutikum

    BERLIN CHEMIE AG [DE] · Granted Thu Apr 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10251938

    Angiopoietin-based interventions for treating cerebral malaria

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10251977

    Compositions and methods for tissue repair with extracellular matrices

    The Regents of the University of California · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10251894

    Anticonvulsant activity of steroids

    The Regents of the University of California · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10253039

    Inhibitors of bacterial DNA gyrase with efficacy against gram-negative bacteria

    The Regents of the University of California · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10251896

    Compositions for improving cell viability and methods of use thereof

    Amylyx Pharmaceuticals, Inc. · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10251923

    Therapeutic uses of mastic gum fractions

    REGENERA PHARMA LTD. · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10253424

    Porous particles and methods of making thereof

    The Board of Regents of the University of Texas System · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10253297

    Stem cell aggregates and methods for making and using

    Regents of the University of Minnesota · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10253333

    DNA-binding proteins and uses thereof

    Sangamo Therapeutics, Inc. · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.